News
IMGN
--
0.00%
--
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results
Business Wire · 4d ago
ImmunoGen (IMGN) Inks Mirvetuximab Development Deal in China
ImmunoGen (IMGN) grants exclusive rights to Huadong Medicine for development and commercialization of mirvetuximab soravtansine in Greater China.
Zacks · 6d ago
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
Business Wire · 10/19 13:45
ImmunoGen inks deal to commercialize antibody-drug conjugate in Greater China
ImmunoGen ([[IMGN]] -0.9%) has agreed to partner with Huadong Medicine Co., Ltd. subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize mirvetuximab soravtansine in Greater China (mainland, Hong
Seekingalpha · 10/19 13:41
Hedge Funds Are Dipping Their Toes Into ImmunoGen, Inc. (IMGN)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress. […]
Insider Monkey · 10/12 18:26
ImmunoGen raises ~$55M via ATM facility
ImmunoGen (IMGN) has raised gross proceeds of ~$54.8M through its At-the-Market ((ATM)) facility pursuant to its Open Market Sale Agreement dated as of September 25 with Jefferies. On October 9, the Company
Seekingalpha · 10/12 12:30
ImmunoGen Raises $54.8M in Gross Proceeds Through its At-the-Market Facility
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has raised gross proceeds of
Benzinga · 10/12 10:31
ImmunoGen's Rare Blood Cancer Candidate Gets Breakthrough Tag
The FDA bestows a Breakthrough Therapy status on ImmunoGen's (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise.
Zacks · 10/06 17:57
ImmunoGen Soars 14% On FDA Breakthrough Designation For Blood Cancer Therapy
Shares of ImmunoGen spiked 14.2% on Monday after the biotechnology company said that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to its IMGN632 for the treatment of a rare and aggressive form of blood cancer.ImmunoGen (IMGN) said that “Breakthrough Therapy designation
SmarterAnalyst · 10/06 06:48
Looking Into Immunogen's Return On Capital Employed
During Q2, Immunogen (NASDAQ: IMGN) brought in sales totaling $15.03 million. However, earnings decreased 22.88%, resulting in a loss of $18.36 million. Immunogen collected $13.29 million in revenue during Q1, but reported earnings showed a $23.81 million loss.What Is ROCE? Return on Capital Employed
Benzinga · 10/05 14:52
MYOK, TEF among premarket gainers
MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals
Seekingalpha · 10/05 12:28
Benzinga Pro's Top 5 Stocks To Watch For Monday, Oct. 5, 2020: REGN, DKNG, BWA, IMGN, FUBO
Today's 5 Stock Ideas:  Regeneron Pharmaceuticals (REGN) - The stock was up 5% following a Friday memo release from the White House stating President Trump was being treated for COVID-19 with “a
Benzinga · 10/05 12:21
ImmunoGen's IMGN632 nabs accelerated review for rare blood cancer
The FDA designates ImmunoGen's (IMGN) IMGN632 a Breakthrough Therapy for the treatment of patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive type of blood cancer that
Seekingalpha · 10/05 10:47
AXGT, AVDL, INMD and IMGN among after-hours movers
Gainers: [[JAX]] +4.5%. [[AXGT]] +4.4%. [[HRI]] +3.1%. [[AVDL]] +2.3%. [[AAL]] +1.7%.Losers: [[TATT]] -6.2%. [[FNKO]] -3.5%. [[IMGN]] -3.0%. [[VIVO]] -2.6%. [[INMD]] -1.6%.
Seekingalpha · 09/25 21:43
ImmunoGen (IMGN) Investor Presentation - Slideshow
The following slide deck was published by ImmunoGen, Inc. in conjunction with this event.
Seekingalpha · 09/17 18:24
ImmunoGen's mirvetuximab shows treatment benefit in FRα-positive ovarian cancer
ImmunoGen (IMGN) announces final data from the FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and Avastin (bevacizumab) in patients with folate receptor alpha (FRα)-positive recurrent, platinum-sensitive
Seekingalpha · 09/17 09:04
ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO
ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO
Business Wire · 09/17 08:01
What Can We Conclude About ImmunoGen's (NASDAQ:IMGN) CEO Pay?
This article will reflect on the compensation paid to Mark Enyedy who has served as CEO of ImmunoGen, Inc...
Simply Wall St. · 09/14 17:20
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference
Business Wire · 09/02 21:30
Webull provides a variety of real-time IMGN stock news. You can receive the latest news about ImmunoGen through multiple platforms. This information may help you make smarter investment decisions.
About IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
More